LeMaitre Vascular, Inc. (NASDAQ:LMAT) Shares Sold by Dimensional Fund Advisors LP

Dimensional Fund Advisors LP trimmed its stake in LeMaitre Vascular, Inc. (NASDAQ:LMAT) by 3.2% during the second quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 641,213 shares of the medical instruments supplier’s stock after selling 21,068 shares during the quarter. Dimensional Fund Advisors LP owned approximately 2.86% of LeMaitre Vascular worth $52,759,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. CANADA LIFE ASSURANCE Co grew its holdings in shares of LeMaitre Vascular by 44.7% in the 1st quarter. CANADA LIFE ASSURANCE Co now owns 22,252 shares of the medical instruments supplier’s stock worth $1,472,000 after acquiring an additional 6,875 shares during the last quarter. Quantbot Technologies LP grew its holdings in shares of LeMaitre Vascular by 1,001.4% in the 1st quarter. Quantbot Technologies LP now owns 7,335 shares of the medical instruments supplier’s stock worth $487,000 after acquiring an additional 6,669 shares during the last quarter. Ranger Investment Management L.P. grew its holdings in shares of LeMaitre Vascular by 1.5% in the 4th quarter. Ranger Investment Management L.P. now owns 912,503 shares of the medical instruments supplier’s stock worth $51,794,000 after acquiring an additional 13,681 shares during the last quarter. Congress Asset Management Co. MA grew its holdings in shares of LeMaitre Vascular by 12.0% in the 1st quarter. Congress Asset Management Co. MA now owns 666,083 shares of the medical instruments supplier’s stock worth $44,201,000 after acquiring an additional 71,411 shares during the last quarter. Finally, Vanguard Group Inc. grew its holdings in shares of LeMaitre Vascular by 2.5% during the fourth quarter. Vanguard Group Inc. now owns 1,548,870 shares of the medical instruments supplier’s stock valued at $87,914,000 after buying an additional 38,303 shares in the last quarter. 84.64% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at LeMaitre Vascular

In other news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, CEO George W. Lemaitre sold 27,030 shares of the company’s stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $86.27, for a total transaction of $2,331,878.10. Following the completion of the sale, the chief executive officer now owns 1,958,328 shares in the company, valued at approximately $168,944,956.56. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Also, Director David B. Roberts sold 3,063 shares of the company’s stock in a transaction dated Tuesday, August 13th. The stock was sold at an average price of $82.07, for a total value of $251,380.41. Following the sale, the director now owns 14,114 shares of the company’s stock, valued at approximately $1,158,335.98. The disclosure for this sale can be found here. In the last quarter, insiders sold 43,251 shares of company stock worth $3,714,994. 10.79% of the stock is owned by corporate insiders.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on LMAT. Barrington Research reiterated an “outperform” rating and set a $92.00 price target on shares of LeMaitre Vascular in a report on Friday, September 20th. StockNews.com downgraded LeMaitre Vascular from a “buy” rating to a “hold” rating in a report on Tuesday, August 27th. Lake Street Capital began coverage on LeMaitre Vascular in a report on Friday, August 2nd. They set a “buy” rating and a $105.00 price target on the stock. Finally, JMP Securities lifted their price target on LeMaitre Vascular from $77.00 to $100.00 and gave the company a “market outperform” rating in a report on Tuesday, August 20th. Two research analysts have rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average target price of $94.40.

LeMaitre Vascular Trading Up 1.6 %

LMAT opened at $91.71 on Friday. The stock has a market cap of $2.06 billion, a price-to-earnings ratio of 60.74, a PEG ratio of 2.41 and a beta of 0.88. LeMaitre Vascular, Inc. has a 1 year low of $44.27 and a 1 year high of $92.90. The stock has a fifty day moving average price of $87.29 and a 200 day moving average price of $78.81.

LeMaitre Vascular (NASDAQ:LMAT) last released its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.52 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.47 by $0.05. The firm had revenue of $55.85 million during the quarter, compared to analysts’ expectations of $54.98 million. LeMaitre Vascular had a return on equity of 12.41% and a net margin of 18.33%. The business’s revenue for the quarter was up 11.4% on a year-over-year basis. During the same quarter last year, the firm earned $0.37 earnings per share. As a group, sell-side analysts forecast that LeMaitre Vascular, Inc. will post 1.85 earnings per share for the current fiscal year.

LeMaitre Vascular Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Thursday, August 29th. Stockholders of record on Thursday, August 15th were paid a dividend of $0.16 per share. The ex-dividend date of this dividend was Thursday, August 15th. This represents a $0.64 annualized dividend and a dividend yield of 0.70%. LeMaitre Vascular’s dividend payout ratio (DPR) is presently 42.38%.

LeMaitre Vascular Profile

LeMaitre Vascular, Inc develops, manufactures, and markets medical devices and implants used in the field of vascular surgery worldwide. It offers human cadaver tissue cryopreservation services; angioscope, a fiberoptic catheter used for viewing the lumen of a blood vessel; embolectomy catheters to remove blood clots from arteries; thrombectomy catheters for removing thrombi in the venous system; occlusion catheters that temporarily occlude the blood flow; and perfusion catheters to perfuse the blood and other fluids into the vasculature.